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Objective. To analyze the long-term impact of the
R92Q mutation of TNFRSF1A in children with periodic
fever, in comparison with children with tumor necrosis
factor receptor–associated periodic syndrome (TRAPS)
with TNFRSF1A structural mutations and children with
periodic fever of unknown origin fulfilling the criteria
for periodic fever, aphthosis, pharyngitis, and adenitis
syndrome (PFAPA).
Methods. The extracellular region of TNFRSF1A
was analyzed in 720 consecutive children with periodic
fever, using denaturing high-performance liquid chro-
matography and DNA sequencing. Followup data on 11
pediatric patients with TNFRSF1A structural mutations
(cysteine or T50M), 23 pediatric patients with an R92Q
substitution, and 64 pediatric patients with PFAPA were
collected during routine clinic visits. The 50-item Child
Health Questionnaire was used to assess health-related
quality of life (HRQOL).
Results. The frequency of typical TRAPS-related
clinical manifestations was significantly lower and the
impact of the disease on HRQOL was significantly
reduced in patients with the R92Q mutation compared
with TRAPS patients carrying structural mutations of
TNFRSF1A. Followup data on 11 TRAPS patients with
TNFRSF1A structural mutations (mean followup 7.9
years), 16 patients with theR92Q substitution (mean
followup 7.3 years), and 64 patients with PFAPA (mean
followup 5.2 years) were available. Patients with R92Q
mutations and patients with PFAPA displayed a higher
rate of self-resolution or amelioration of the fever episodes
than did TRAPS patients with structural mutations.
Conclusion. Although some cases may progress to
a more chronic disease course, the majority of children
with an R92Q mutation of the TNFRSFA1 gene show a
milder disease course than that in children with
TNFRSFA1 structural mutations and have a high rate of
spontaneous resolution and amelioration of the recur-
rent fever episodes.
Tumor necrosis factor receptor–associated peri-
odic syndrome (TRAPS) is an autosomal-dominant dis-
ease caused by mutations of the type I tumor necrosis
factor receptor (TNFRI) gene (TNFRSF1A) (1,2). The
TNFRSF1A mutations reported in TRAPS patients in-
clude missense substitutions, mainly affecting the highly
conserved cysteine residues of the extracellular cysteine-
rich domains involved in disulfide bond formation and in
the folding of the extracellular portion of TNFRI (3,4).
These genetic variants (also defined as structural muta-
tions) have a high penetrance, and the corresponding
phenotype is characterized by a severe disease course.
Patients display long-lasting fever episodes (duration of
1–3 weeks) associated with rash, arthralgia, myalgia, and
abdominal pain. Progression toward a more chronic
disease course and renal amyloidosis is a possible long-
term complication in adulthood (5). Patients may re-
quire prolonged treatment with steroids and use of
second-line drugs (3–5).
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1141Among Caucasian populations, the R92Q muta-
tion is the most frequently observed variant of the
TNFRSF1A gene in children with periodic fever (6,7).
R92Q is a missense and low-penetrance mutation with
no relevant impact on the structure and function of the
mutated protein and is usually associated with a milder
disease course, characterized by episodes of fever lasting
only a few days, lower intensity of disease-associated
symptoms, and a much lower prevalence of amyloidosis
(3,4). Notably, according to different studies, the allele
frequency of the R92Q variant in the general population
ranges from 1.2% to 4% (3,4,6,8). Apart from the
description of very few anecdotal cases of renal amyloid-
osis in adults (9), no information is available on the
long-term clinical profile of patients affected with
TRAPS who are carriers of the R92Q mutation.
Indeed, only 10–20% of children with a clinical
picture consistent with a periodic fever turn out to be
carriers of at least one mutation of the genes known to
be associated with monogenic periodic fevers such as
familial Mediterranean fever, mevalonate kinase defi-
ciency, and TRAPS (10). The clinical spectrum of the
large group of mutation-negative children with periodic
fever is extremely variable. In the pediatric population,
the most common cause of periodic fever is a clinical
entity characterized by recurrent episodes of fever,
known under the acronym PFAPA (periodic fever,
aphthosis, pharyngitis, and adenitis syndrome) (6,11,12).
The genetic basis of this syndrome is not yet docu-
mented, and usually spontaneous resolution of the fever
episodes will occur a few years after symptom onset. In
the present study, we chose to analyze mutation-negative
patients who fulfilled the PFAPA criteria, in order to
have a more homogeneous disease control group.
The aim of the present study was to analyze the
long-term clinical course in children with periodic fever
carrying the R92Q mutation, as compared with that in
TRAPS patients carrying structural mutations of
TNFRSF1A and patients with periodic fever of unknown
origin fulfilling the criteria for PFAPA.
PATIENTS AND METHODS
Patients. Starting from 2002, a nationwide laboratory
facility for the genetic diagnosis of recurrent fevers in children
was established at the G. Gaslini Institute (10). Up to July
2009, specimens from 720 consecutive patients with periodic
fever were received from pediatric centers located all over Italy
for molecular analysis of the MVK, MEFV,o rTNFRSF1A
genes. The extracellular region (from exon 1 to exon 6) of the
TNFRSF1A gene was analyzed using denaturing high-
performance liquid chromatography and DNA sequencing of
amplimers displaying anomalous chromatographic patterns, as
previously described (10).
Clinical data were collected at the time of molecular
screening and at the last followup visit, using a standardized
questionnaire (10). Informed consent was obtained from all
subjects, with approval from the G. Gaslini Institute Ethics
Board. The following variables were considered: family history
(recurrent fever and/or manifestations of inflammation consis-
tent with an autoinflammatory disease), number of fever
episodes per year, mean duration of fever episodes, and
presence and frequency (never, sometimes, often, always) of
the clinical manifestations associated with episodes of fever.
A spontaneous disease course was classified according
to the following 4 categories: 1) spontaneous resolution (no
fever episodes during the last 6 months of followup, in the
absence of any continuous steroid and/or second-line treat-
ment); 2) spontaneous improvement (reduction of 30% in
the number of fever episodes during the last 6 months of
followup, in the absence of any continuous steroid and/or
second-line treatment); 3) stable disease (reduction of 30%
in the number of fever episodes, in the absence of any
continuous steroid and/or second-line treatment; or 4) wors-
ening of the disease (any increase in the frequency or duration
of fever episodes or appearance of new major clinical mani-
festations [i.e., amyloidosis], in the absence of any continuous
steroid and/or second-line treatment). In addition, the thera-
peutic strategy used during the disease course was investigated
according to the following categories: 1) need for short courses
of steroids administered on demand for not more than 5
consecutive days; 2) need for steroid courses administered on
demand for a period longer than 5 days; or 3) need for a
second-line treatment, due to steroid resistance or steroid
dependency. Sixty-four pediatric patients who fulfilled the
current criteria for PFAPA (12,13) and were negative for
mutations of the MVK, TNFRSF1A, or MEFV gene were
analyzed as disease controls.
Evaluation of health-related quality of life (HRQOL).
The Italian national language version of the parent-
administered 50-item Child Health Questionnaire (CHQ-PF50)
(14) was used to assess the quality of life of the patients. The
CHQ is a generic, self-administered instrument designed to
assess the physical, emotional, and social components of health
status in children. It includes 15 health concepts (score range
0–100) that explore both physical and psychosocial domains
(15). Two summary measures based on the US normative
standard, the physical summary score (PhS) and the psycho-
social summary score (PsS), are provided; the summary mea-
sures are standardized to have a mean score of 50 and an SD
of 10. Higher scores in the scales indicate better HRQOL. The
CHQ-PF50 questionnaire was administered to all patients
carrying TNFRSF1A gene mutations. The questionnaire was
administered at the time of the first evaluation at the center.
An international sample of 3,315 healthy children (52.2% of
whom were female, mean  SD age 11.2  3.8 years) con-
stituted the healthy control group, as previously described (16).
Statistical analysis. Differences among groups were
evaluated using the nonparametric Kruskal-Wallis test. Symp-
tom frequency was evaluated using the chi-square test. Differ-
ences in HRQOL were analyzed with Student’s t-test.
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Genotype characterization. From 2002 onward, 34
pediatric patients carrying mutations of the TNFRSFA1
gene were identified (Table 1). Eleven patients dis-
played mutations associated with a substantial modifica-
tion of the structure of the protein (structural muta-
tions) (3). Twenty-three patients carried the low-
penetrance R92Q substitution in a heterozygous state.
Two sisters carried the C88Y mutation (Table 1). Three
patients with the R92Q mutation (2 boys and 1 girl) were
siblings; the 2 brothers were heterozygous, whereas the
sister was homozygous for the same variant (Table 1).
Nine (82%) of the 11 children carrying
TNFRSF1A structural mutations had a family history
consistent with an autoinflammatory disease (including
renal amyloidosis in 3 families), for a total of 24 affected
individuals. In each family, all of the affected members
screened for TNFRSF1A carried the same mutation as
that found in the proband. Complete penetrance was
observed in all families harboring a structural mutation.
Apart from the family with 3 affected children, a
positive family history of recurrent fever was noted in
only 1 patient carrying the R92Q mutation. In this case,
the mother reported experiencing recurrent episodes of
fever during childhood and was positive for the R92Q
mutation.
Asymptomatic parents of 12 patients carrying
the R92Q mutation were also screened. In all cases, at
least 1 parent carried the same variant as that in the
proband. In the family of the 3 affected children with the
Table 1. Mutations of TNFRSF1 and other genes involved in auto-
inflammatory syndromes in children with periodic fever














* One of these patients carried the mutation in a homozygous state.
† Identified in patients with the R92Q substitution.
Table 2. Baseline demographic and clinical characteristics of the patients with TRAPS, patients with the R92Q mutation, and
patients with PFAPA*
Patients with
TRAPS (n  11)
Patients with
R92Q (n  20)
Patients with
PFAPA (n  64) P†
No. male/no. female 6/5 11/9 38/26 NS
Age at disease onset, mean (range) years 3.1 (0.3–7.1) 3.6 (0.6–13) 1.6 (0.3–4.7) 0.005
Age at molecular analysis, mean (range) years 5.6 (1–9) 6.1 (1.2–15) 5.7 (1.5–15.1) NS
Fever duration, mean (range) days 15.3 (3–18) 5.9 (3–15) 4.6 (2–10) 0.002
Clinical characteristic
Periodicity 27 40 62 0.05
Oral aphthosis 9.1 35.6 62.5 0.001
Erythematosus pharyngitis 54.5 65 82.8 NS
Exudative pharyngitis 45.4 50 59.3 NS
Enlargement of cervical lymph nodes 72.7 65 85.9 NS
Pain at cervical lymph nodes 18 45 51 NS
Rash 45.4 20 28.1 NS
Conjunctivitis 9 10 17 NS
Periorbital edema 36.3 0 4.6 0.003
Thoracic pain 27.2 5 3.1 0.04
Abdominal pain 81.8 40 50 NS
Diarrhea 18.1 15 26.5 NS
Vomiting 27.2 30 15.6 NS
Splenomegaly 0 25 14 NS
Arthritis 27.2 0 6.2 NS
Arthralgia 63.6 40 43.7 NS
Myalgia 63.6 35 43.7 NS
Headache 54.5 30 31.2 NS
* Except where indicated otherwise, values are the percent of patients. TRAPS  tumor necrosis factor receptor–associated
periodic syndrome; PFAPA  periodic fever, aphthosis, pharyngitis, and adenitis syndrome; NS  not significant.
† Determined by Kruskal-Wallis test for heterogeneity.
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but were totally asymptomatic.
A positive family history of recurrent fever in
childhood (mainly related to 1 parent only) was reported
in 9 (14%) of 64 patients with PFAPA. Among children
carrying the R92Q substitution, additional mutations
co-occurring in other genes known to be associated with
periodic fevers were found; 2 of these patients were
compound heterozygous for the MVK gene (I268T/
V377I in 1 patient and H20Q/V377I in the other patient)
(17), while 1 patient was homozygous for the T237S
variant of the MVK gene. These latter 3 patients were
considered affected by mevalonate kinase deficiency,
and therefore were excluded from the present study.
Clinical and laboratory features of the patients
at baseline. The main clinical findings observed from
disease onset to the time of molecular analysis (base-
line) were noted in 11 children carrying TNFRSF1A
structural mutations (defined as TRAPS patients), 20
children with the R92Q substitution, and 64 patients
with PFAPA, as shown in Table 2. Patients carrying
structural mutations displayed prolonged episodes of
fever, with a mean duration of fever of 15.3 days (range
3–18 days) compared with a mean of 5.9 days (range
3–15 days) in patients with the R92Q variant and a mean
of 4.6 days (range 2–10 days) in patients with PFAPA.
The mean number of attacks per year was 6.4 (range
1–12) in TRAPS patients with structural mutations, 10.3
in patients with the R92Q mutation (range 3–20), and
14.3 (range 4–20) in patients with PFAPA. At baseline,
all patients displayed recurrent episodes of fever only,
without other relevant symptoms between the flares.
As shown in Table 2, the Kruskal-Wallis test for
heterogeneity revealed an increased prevalence of peri-
orbital edema and thoracic pain in patients carrying
TNFRFS1A structural mutations, whereas patients
with PFAPA had an earlier onset of disease and a
higher rate of periodicity of fever episodes and oral
aphthosis when compared with the other 2 subgroups
(Table 2). Moreover, when the clinical symptoms were
compared, taking into account not only their presence/
absence but also their frequency (never/sometimes/
often/always), an even clearer heterogeneity was ob-
served among the 3 subgroups. Indeed, pediatric
patients with TRAPS carrying structural mutations of
TNFRFS1A displayed a higher frequency of abdominal
pain, skin rash, and limb pain (myalgia and/or arthralgia)
compared to children with the R92Q mutation and
children with PFAPA (Figure 1). Conversely, a higher
frequency of either erythematous or exudative pharyn-
gitis was observed in patients with PFAPA and, to a
Figure 1. Frequency of typical clinical manifestations in children with
tumor necrosis factor receptor–associated periodic syndrome (n  11;
solid bars), children with the R92Q substitution (n  20; gray shaded
bars), and children with periodic fever, aphthosis, pharyngitis, and
adenitis syndrome (n  64; open bars), according to whether the
symptom never occurred (score 0), sometimes occurred (score 1),
often occurred (score 2), or always occurred (score 3). P values
indicate the significance of the differences between groups, according
to the chi-square test for heterogeneity.
1144 PELAGATTI ET ALlesser extent, in patients with the R92Q mutation com-
pared with patients with TRAPS (Figure 1).
Median laboratory values at the time of fever
episodes were available for 46 patients (8 with TRAPS,
12 with the R92Q mutation, and 26 with PFAPA)
(Table 3). A high degree of variability in the main
laboratory parameters was observed, especially in the
R92Q subgroup (Table 3). Apart from a higher elevation
of the C-reactive protein level in patients with TRAPS
and patients with the R92Q mutation, no other major
differences were detected among the 3 subgroups.
Impact of different TNFRSF1A mutations on
HRQOL. As shown in Figure 2, scores on the 15
subscales of the CHQ-PF50 and the 2 summary scores
(PhS and PsS) were determined at the time of molecular
analysis for 9 pediatric patients with TRAPS and 14
Table 3. Laboratory parameters during fever episodes in patients with TRAPS, patients with the R92Q









3 16.7 (11.7–41.5) 11.7 (3.5–39.0) 13.7 (4.3–19.8)
Neutrophils,  10
3/mm
3 10.6 (9.0–35.8) 9.3 (2.7–34.6) 8.6 (2.5–16.3)
Monocytes,  10
3/mm
3 0.57 (0.4–0.8) 0.84 (0.3–1.5) 1.01 (0.4–1.7)
Lymphocytes,  10
3/mm
3 2.28 (1.1–5.0) 3.71 (0.5–8.3) 3.14 (1.4–5.9)
Hemoglobin, gm/liter 10.8 (9.1–12.5) 11 (9.3–14.1) 11.6 (11–12.8)
Platelet count,  10
3/mm
3 527 (270–595) 354 (90–433) 352 (220–545)
ESR, mm/first hour 70 (28–95) 57 (26–79) 41 (9–93)
CRP, mg/dl 13.2 (1.3–29)† 11.1 (2–37) 6.1 (2–13.2)
* Values are the median (range). WBCs  white blood cells; ESR  erythrocyte sedimentation rate;
CRP  C-reactive protein.
† P  0.05 versus the other groups, by nonparametric Kruskal-Wallis test for heterogeneity. In post hoc
analysis by Mann-Whitney U test, differences between groups were as follows: P not significant for
patients with tumor necrosis factor receptor–associated periodic syndrome (TRAPS) versus patients with
R92Q, P  0.005 for patients with TRAPS versus patients with periodic fever, aphthosis, pharyngitis, and
adenitis syndrome (PFAPA), and P  0.02 for patients with R92Q versus patients with PFAPA.
Figure 2. Diagram showing the scores for health-related quality of life (HRQOL) on the
50-item Child Health Questionnaire (score range 0–100) in pediatric patients with tumor
necrosis factor receptor–associated periodic syndrome (TRAPS) with structural mutations
of the TNFRSF1A gene (solid diamonds) and pediatric patients with the R92Q mutation
(shaded squares), in comparison with healthy children (open diamonds). HRQOL was
assessed as the mean of the 2 summary scores for the physical domain (PhS) and the
psychological domain (PsS) and the 15 subscales. Asterisks for each item indicate the
P values for significant or nonsignificant (NS) differences in HRQOL between TRAPS
patients/patients with R92Q as compared with healthy controls.   P  0.05;   P  0.01;
  P  0.001, by Mann-Whitney U test.
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with reference values for healthy controls. TNFRSF1A
structural mutations were associated with a severe im-
pairment in both the physical domain (PhS score) and
the psychosocial domain (PsS score) when compared to
the scores in the healthy controls (Figure 2).
Structural mutations had a major impact on most
of the items described to assess the HRQOL. The most
reduced scores among the CHQ-PF50 health concepts
were those related to physical domains, such as global
health, physical functioning, and bodily pain/discomfort.
However, several items related to psychosocial domains,
such as general health perception, emotional impact on
parents, family activities, and time impact on parents
were also variably impaired (Figure 2). The significantly
lower values with regard to health perception, as com-
pared with the values from the preceding year, were
consistent with the tendency toward worsening of the
disease, as was observed in these patients. Conversely,
the impact of disease activity was less severe in patients
carrying the R92Q mutation. Notably, the most affected
concepts, in comparison with healthy controls, were
those associated with global health perception (global
health, general health perception, and emotional impact
on parents).
Difference in spontaneous disease course in chil-
dren with the R92Q mutation compared with children
with TRAPS. Data on long-term followup were available
for 11 children with TRAPS, 16 children carrying the
R92Q mutation, and 64 children with PFAPA. At the
time of the study, the mean followup from the time of
disease onset was 7.9 years (range 1.6–15 years) for
TRAPS patients, 7.3 years (range 1.7–14.3 years) for
children with the R92Q substitution, and 5.2 years
(range 1.2–13.1 years) for patients with PFAPA. All
patients had at least 1 year of followup after the
molecular screening.
The spontaneous disease course in the absence of
any continuous steroid and/or second-line treatment was
evaluated in all patients (Figure 3A). A spontaneous
resolution of fever episodes was observed in 4 (25%) of
16 patients with the R92Q mutation, including the
patient carrying the mutation in a homozygous state,
and in 10 (16%) of 64 patients with PFAPA (Figure 3A).
A reduction of more than 30% in the frequency of the
fever episodes from baseline was observed in 9 (56%) of
16 patients with the R92Q mutation and 33 (52%) of 64
patients with PFAPA (Figure 3A). Conversely, no spon-
taneous resolution or reduction of the fever episodes
was observed in patients with TNFRSF1A structural
mutations (Figure 3A). One (6%) of the 16 patients with
the R92Q mutation (age at followup 16 years, disease
duration 9 years) and 16 (25%) of the 64 patients with
Figure 3. Course of spontaneous disease, defined according to cate-
gories of spontaneous resolution, spontaneous improvement, stable
disease, or worsened disease (see Patients and Methods), before any
continuous treatment (A), and therapeutic strategy at the time of the
last followup (B) in the 3 subgroups of pediatric patients. The mean
followup from disease onset was 7.9 years (range 1.6–15 years) for
patients with tumor necrosis factor receptor–associated periodic syn-
drome (TRAPS) (n  11; solid bars), 7.3 years (range 1.7–14.3 years)
for children with the R92Q substitution (n  16; shaded bars), and 5.2
years (range 1.2–13.1 years) for children with periodic fever, aphthosis,
pharyngitis, and adenitis syndrome (n  64; open bars). P values
indicate the significance of the differences in the TRAPS patients
compared with the other groups, according to the chi-square test for
heterogeneity. NSAID  nonsteroidal antiinflammatory drug.
1146 PELAGATTI ET ALPFAFA displayed a persistence of fever episodes with-
out a significant decrease in the frequency of these
episodes when compared with that at baseline.
An increased frequency of fever episodes was
observed in 5 patients with PFAPA (8%) (Figure 3A).
Two patients with the R92Q mutation (13%) showed a
worsening of the disease, due to the development of a
chronic course that required continuous second-line
treatment. The ages at followup of these 2 patients were
16.3 years and 19.8 years, respectively, and the disease
durations were 12.3 years and 16.8 years, respectively.
The retrospective analysis of the clinical manifesta-
tions at the time of disease onset in the 3 patients with
R92Q mutations who displayed a stable or progressive
disease course did not reveal substantial differences
when compared with the other patients carrying the
same variant (Table 2). During followup, all patients
with structural TNFRSF1A mutations displayed a signif-
icantly more severe disease course, with persistence of
stable disease in 6 patients (54%) and an increase in the
frequency or duration of fever episodes in 5 patients
(46%) (Figure 3A).
Therapeutic strategy during followup. The ther-
apeutic strategy used in the different subgroups during
followup was then investigated (Figure 3B). Due to the
long duration of fever episodes, all TRAPS patients with
structural mutations were treated with prolonged
courses of steroids (more than 5 days). Due to high
cumulative steroid doses, 5 of these patients were
treated with second-line biologic therapy (Figure 3B).
Recombinant interleukin-1 receptor antagonist (anak-
inra) was used as a first-choice therapy in 4 children with
TRAPS, resulting in a good and persistent response
(18). One 12-year-old girl was initially treated with
etanercept and showed a good initial response; however,
after 1 year, etanercept was withdrawn due to the
occurrence of new disease flares. The introduction of
anakinra in this patient has led to effective and persis-
tent control of both her clinical symptoms and labora-
tory results over a followup period of 3 years.
The therapeutic strategy chosen for patients car-
rying the R92Q variant was largely different from that
chosen for patients with TRAPS. Indeed, 11 (68%) of 16
patients with the R92Q mutation were successfully
treated with short-term steroids on demand (Figure 3B).
Most of these patients displayed a complete response
after a single dose of steroids. In 2 patients, treatment
with nonsteroidal antiinflammatory drugs (NSAIDs)
resulted in control of the clinical manifestations. Only 3
patients (18%) with the R92Q mutation required a
prolonged period of steroid treatment to control their
clinical and laboratory manifestations. In 1 of these
patients, treatment with colchicine was able to signifi-
cantly reduce the frequency and intensity of fever epi-
sodes. The 2 patients in whom a chronic disease course
developed became steroid-dependent and were treated
with biologic agents. One patient was treated with
anakinra, and the disease showed a persistent and
complete response after 1 month of treatment (18). The
other patient did not respond to treatment with etaner-
cept and displayed a partial response to anakinra, char-
acterized by the absence of clinical manifestations and a
slow tapering of the steroid dose, but with a persistent
slight elevation in the levels of acute-phase reactants,
including the level of serum amyloid A.
Short-term treatment with steroids was the treat-
ment of choice in the majority of patients with PFAPA
(54 [84%] of 64) (Figure 3B). All patients displayed
prompt control of the clinical manifestations. Other
patients were treated exclusively with NSAIDs on de-
mand. Due to the persistence of frequent fever episodes,
6 patients were treated with tonsillectomy, resulting in a
good response.
DISCUSSION
In the present study, we compared patients with
recurrent fever according to subgroups of patients car-
rying the R92Q variation, patients carrying structural
mutations in TNFRSF1A, and mutation-negative pa-
tients with PFAPA. In our study, children with the R92Q
mutation displayed a higher degree of similarity with the
PFAPA subgroup than with the TRAPS patients carry-
ing structural mutations. This was true for many clinical
features, such as the prevalence of a positive family
history of recurrent fever and the duration and fre-
quency of fever episodes. We also showed that the
incidence and the frequency of the most typical TRAPS-
related clinical manifestations (chest pain, abdominal
pain, rash, limb pain, and periorbital edema) in patients
with the R92Q variant were much more similar to those
observed in patients with PFAPA than those observed in
patients with structural TNFRSF1A mutations. The less
severe effect of the R92Q mutations was also confirmed
by the milder impact of the disease on many aspects of
HRQOL, in contrast to the much more severely affected
patients with structural TNFRSF1A mutations.
Together with the incidence and frequency of the
fever-associated clinical manifestations at the time of the
molecular analysis (6,19), the longitudinal observational
data on the patients during their long-term followup are
an important indicator of the actual impact of the
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This is particularly true for children with periodic fever,
especially the mutation-negative patients, who experi-
ence a relevant rate of spontaneous resolution of the
fever episodes over the long term (12). For this reason,
we compared the long-term clinical course of pediatric
patients with the R92Q mutation with that of pediatric
patients with TRAPS and pediatric patients with
PFAPA.
Fortunately, none of our patients developed any
of the most typical long-term complications, such as
renal amyloidosis, considered to be a major marker of
long-term disease severity in adult patients (3–5,19).
However, in the present study, we observed that most
of the patients with an R92Q mutation experienced a
rate of spontaneous resolution or amelioration of fever
episodes similar to that observed in mutation-negative
patients with a PFAPA phenotype. In this context, the
slightly higher percentage of patients with the R92Q
mutation experiencing complete resolution, as com-
pared with patients with PFAPA, could be related to a
longer followup in the former group. The relatively
benign disease course observed in patients with the
R92Q mutation was also consistent with the therapeutic
strategy used in these patients, generally similar to that
reported in patients with PFAPA, i.e., short courses of
steroids on demand that were usually effective after
single-dose administration (20).
In addition to the low frequency of a positive
family history of recurrent fever observed in the majority
of the parents of R92Q-positive patients, the results of
our followup study add further proof to support the
notion of the actual limited pathogenic relevance of
this variant in the context of periodic fevers. However,
as was also observed in the present study, a few pati-
ents carrying the same mutation may present with a
more severe disease course (9,19), requiring an aggres-
sive therapeutic approach. This observation has raised
the hypothesis of a possible proinflammatory effect of
the R92Q mutation that, concomitant with other envi-
ronmental and genetic factors, may contribute to the
inflammatory phenotype observed in these patients. It
was also suggested that R92Q mutations could act as a
possible susceptibility factor in other autoinflammatory
diseases (21) or chronic inflammatory conditions, such
as Behc ¸et’s disease (22), multiple sclerosis (23), and
juvenile idiopathic arthritis (24).
Whether these latter observations simply reflect
the relatively high prevalence of the R92Q mutation in
the normal population is still a matter of debate (8,25).
Indeed, we recently reported that the allele frequency
of R92Q in 265 children with periodic fever (2.45%)
did not differ significantly from the allele frequency
in healthy subjects from the same Italian population
(2.25%) (6). The same observation was also reported in
a parallel Dutch study (26), supporting the hypothesis
that the R92Q mutation should be considered more as a
polymorphism than as a pathogenic variant.
The mild impact of the R92Q mutation has also
been confirmed by a number of ex vivo and in vitro
observations in studies aimed at identifying the func-
tional impact of different mutations of TNFRSF1A.
Structural mutations of TNFRSF1A have been associ-
ated with the following pathogenic consequences: 1)
defective shedding of TNFRI from cell membranes after
cell activation (3,6), 2) impaired TNF-induced apoptosis
in fibroblasts and neutrophils (6,27), and 3) formation of
intracellular aggregates of mutated TNFRI that cause
impaired trafficking of the receptor to the cell mem-
brane (28,29). Recent evidence supports the hypothesis
that intracellular accumulation of the mutated receptor
causes a ligand-independent activation of kinases, lead-
ing to aberrant cytokine production (30). Notably, in
all of the above-mentioned studies, the behavior of the
R92Q variant of TNFRI was much more similar to that
of the wild-type receptor than to that of the structural
TNFRSF1A mutations (3,6,28,29).
These observations, in accordance with the ge-
netic and clinical findings reported above, seem to
represent a reappraisal of the actual pathogenic role of
this variant. In our study, we provide evidence that
patients with the R92Q mutation do not present the
same clinical picture and outcomes as those observed in
patients with TRAPS, and that patients with the R92Q
mutation do have similarities with many other mutation-
negative patients with periodic fever.
Despite the relatively small number of patients
with TNFRSF1A mutations analyzed in the present
study, our decision to screen all 3 genes and to longitu-
dinally observe the patients allowed us to verify the
actual incidence and clinical impact of the R92Q muta-
tion in a homogeneous population of children with
periodic fever. International registries on these rare
diseases, such as Eurofever (available at http://
www.printo.it/eurofever), will facilitate verification of
these observations in a larger number of patients from
different countries and of different ethnicities, which
might conclusively change the current thinking about the
clinical significance of the R92Q mutation.
In summary, our study shows that the majority of
children with the R92Q mutation of TNFRSFA1 display
a milder disease course as compared with patients with
1148 PELAGATTI ET ALstructural mutations and have a higher rate of sponta-
neous resolution and amelioration of episodic fever.
This clinical observation supports the notion of the
limited pathogenic role of this variant. Based on these
data and on the prevalence of this variant in the normal
population, great caution should be taken in the inter-
pretation of positive findings for the R92Q variant in
molecular analysis of children with periodic fever, in
either epidemiologic studies or clinical studies.
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Clinical Images: Hippokrates confirmed by positron emission tomography
The patient, a 52-year-old man with a 35–pack-year smoking history, presented with the acute onset of arthralgias and bone pain
in both knees, shins, and ankles, as well as clubbing of the fingers (“Hippokrates fingers”) and toes (A), first noted 8 weeks earlier.
Radiography and computed tomography (CT) of the lungs revealed extensive scarring of the right upper lobe, due to tuberculosis
that had been successfully treated 28 years earlier; however, no pulmonary mass could be identified. Therefore,
18F-fluorodeoxyglucose
positron emission tomography in combination with CT was performed, and marked tracer accumulation was detected in the entire right
upper lobe. In addition, this examination also showed markedly increased metabolism symmetrically along the contours of the femur,
tibia, talus, and toes (B), compatible with inflammatory periostitis, a hallmark of hypertrophic osteoarthopathy. The patient was referred
for surgery; a lobectomy was performed and revealed adenocarcinoma with infiltration of venules, but no lymph node metastasis
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